12/3
08:42 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock, down previously from $82.00.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock, down previously from $82.00.
12/3
08:34 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
12/3
06:31 am
bmrn
BioMarin downgraded to Market Perform from Outperform at Leerink
Low
Report
BioMarin downgraded to Market Perform from Outperform at Leerink
12/3
06:10 am
bmrn
BioMarin downgraded to Market Perform from Outperform at Leerink
Low
Report
BioMarin downgraded to Market Perform from Outperform at Leerink
11/6
08:10 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "hold" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $61.00 price target on the stock, down previously from $73.00.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "hold" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $61.00 price target on the stock, down previously from $73.00.
11/6
08:10 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "hold" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $61.00 price target on the stock, down previously from $73.00.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "hold" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $61.00 price target on the stock, down previously from $73.00.
11/6
07:46 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
11/6
05:19 am
bmrn
BioMarin downgraded to Hold from Buy at Stifel
Low
Report
BioMarin downgraded to Hold from Buy at Stifel
11/3
07:45 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
11/3
07:45 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/28
01:13 pm
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
10/28
01:13 pm
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
10/28
11:20 am
bmrn
Rating for BMRN
Medium
Report
Rating for BMRN
10/28
11:20 am
bmrn
Rating for BMRN
Medium
Report
Rating for BMRN
10/28
10:03 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/28
10:03 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.
10/28
09:56 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/28
09:06 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/28
09:06 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/28
07:11 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/28
07:11 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
10/28
07:02 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
10/28
07:02 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wolfe Research.
10/9
08:50 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
9/8
08:05 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at HC Wainwright. They set a "neutral" rating and a $60.00 price target on the stock.
Medium
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at HC Wainwright. They set a "neutral" rating and a $60.00 price target on the stock.